Vivos Therapeutics (NASDAQ: VVOS) has announced first time, peer-reviewed published data confirming that the Vivos Daytime-Nighttime Appliance (DNA) is both safe and efficacious in treating children suffering from obstructive sleep apnea (OSA).
According to Vivos, the results from a multicenter clinical trial—published in the European Journal of Pediatrics—represent a significant milestone in the fight against OSA, one of the most underdiagnosed and undertreated pediatric health conditions. The DNA appliance is part of Vivos’ Complete Airway Repositioning and Expansion (C.A.R.E.) line of devices.
In a statement, Kirk Huntsman, chairman and CEO of Vivos, commented, “We believe this data signals a new era in pediatric OSA treatment. For over a century, surgery has been the go-to treatment for children with OSA. With these results, parents and providers now have strong evidence supporting our DNA appliance as a safe, non-surgical alternative. No child should face invasive surgery without first considering our FDA cleared appliance available through Vivos-trained healthcare providers.”
